A Phase I, Open Label Study Investigating the Disposition of 25 mg/m2 [14C]-AVE8062 (1.85 MBq, 50 microCi) Administered at Cycle 1 as a 30-minute Intravenous Infusion to Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2011
At a glance
- Drugs Ombrabulin (Primary) ; Cisplatin
- Indications Solid tumours
- Focus Pharmacokinetics
- 04 Nov 2011 Actual patient number is 3 as reported by ClinicalTrials.gov record.
- 21 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.